ETI (CFTR Triple Therapy): Clinical Opportunities
eCysticFibrosis Review
by eCysticFibrosis Review
1y ago
The advent of triple CFTR modulator therapy – ETI (elexacaftor/tezacaftor/ivacaftor) — poses a number of clinical questions. Are three agents really better than two? For which patients, in what circumstances? What does the CF Team need to understand to ensure their patients get maximum benefit?  Join us as we explore these questions with guest author Professor Edward McKone MD, from St. Vincent’s University Hospital and University College Dublin School of Medicine, in this eCysticFibrosis Review podcast.  Take our post-test to claim CME credits. Read this podcast's co ..read more
Visit website
Race, Ethnicity, and Cystic Fibrosis
eCysticFibrosis Review
by eCysticFibrosis Review
1y ago
Race and ethnicity. How do they affect a patient’s ability to receive a timely and accurate cystic fibrosis diagnosis? How do the social determinants of health limit access to appropriate CF treatment and produce poorer outcomes?  That’s what we’re here to talk about today with Dr. Jennifer Taylor-Cousar from National Jewish Health and Children’s Hospital Colorado in this eCysticFibrosis Review podcast.  Take our post-test to claim CME credits. Read this podcast's companion newsletter here. Hosted on Acast. See acast.com/privacy for more information ..read more
Visit website
CF and COVID-19: The Data and the Real World
eCysticFibrosis Review
by eCysticFibrosis Review
1y ago
Do cystic fibrosis lung impairment and the COVID-19 virus create the disastrous combination they would seem to make? What do the currently published data say about the clinical effects of the pandemic on people living with CF? How have the safety-mandated lockdowns and clinic closures affected CF care teams’ ability to effectively maintain their patients’ health? What information out there is proved, what’s speculation, and what is simply unknown?  These questions are the focus of this eCysticFibrosis Review Special COVID Edition issue. Lisa Saiman MD, MPH ..read more
Visit website
Clinical Considerations: New Anti-Inflammatories & New CFTR Modulators
eCysticFibrosis Review
by eCysticFibrosis Review
1y ago
New CFTR modulators for F508del mutations? New research into reducing inflammation in the CF lung?  In this issue, Dr. Jennifer Taylor-Cousar from National Jewish Health in Denver explains the potential clinical impact of new and emerging CF disease modifying therapies. Take our post-test to claim CME credits. To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information ..read more
Visit website
Continuous Alternating Therapies: A Clinical Perspective
eCysticFibrosis Review
by eCysticFibrosis Review
1y ago
Inhaled antibiotics have become the foundation of treating chronic respiratory tract Pseudomonas infection in individuals with cystic fibrosis. But what happens when inhaled monotherapy doesn’t sufficiently manage the symptoms? Which patients are appropriate candidates for treatment with multiple inhaled agents?  Which medications are appropriate for continuous alternating therapy (CAT)? In this Issue, Dr. Elliott Dasenbrook from the Cleveland Clinic brings the evidence he analyzed in his recent eCysticFibrosis Review Newsletter issue (Vol 8; Issue 10) into the clinic ..read more
Visit website
Clinical Insight: CFTR Modulators
eCysticFibrosis Review
by eCysticFibrosis Review
1y ago
In this issue, Dr. Gregory Sawicki — Associate Professor of Pediatrics at Harvard Medical School and Director of the Cystic Fibrosis Center at Boston Children’s Hospital — discusses how the recent findings about the real-world use of CFTR modulators can impact clinical practice. Take our post-test to claim CME credits. To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information ..read more
Visit website
Clinical Approaches to MDR Lung Infections
eCysticFibrosis Review
by eCysticFibrosis Review
1y ago
Multidrug resistant lung infections present an increasingly common and increasingly dangerous threat to all individuals with cystic fibrosis.  Common CF pathogens — Pseudomonas aeruginosa, Burkholderia cepacia complex, Achromobacter xylosoxidans, Stenotrophomonas maltophilia — are all showing increasing resistance to clinicians’ usual antibiotic armamentarium. In this issue, Dr. Claire Elson, from the University of Missouri Kansas City School of Pharmacy, and Dr. Christopher Oermann, from the UMKC School of Medicine, describe strategies for the clinical management of these resis ..read more
Visit website
P. aeruginosa eradication and reinfection
eCysticFibrosis Review
by eCysticFibrosis Review
1y ago
Volume 5, Issue 4. In this issue of eCysticfibrosis Review Dr. Ratjen discusses the challenges of P. aeruginosa eradication. He explains the importance to treat early and available treatment options. He also addresses whether treatment should be repeated in patients who develop recurrence of infection and how to handle patients failing eradication therapy. The post P. aeruginosa eradication and reinfection appeared first on DKBmed Radio. Hosted on Acast. See acast.com/privacy for more information ..read more
Visit website
Pulmonary exacerbations: diagnoses, and therapeutic regimens
eCysticFibrosis Review
by eCysticFibrosis Review
1y ago
Volume 5, Issue 2. In this podcast Dr. Patrick Flume, Professor of Medicine and Pediatrics at the Medical University of South Carolina in Charleston, discusses pulmonary exacerbation. He provides patient case scenarios to understand the importance of pulmonary exacerbation and the ability to identify when it occurs. The post Pulmonary exacerbations: diagnoses, and therapeutic regimens appeared first on DKBmed Radio. Hosted on Acast. See acast.com/privacy for more information ..read more
Visit website
What Does CFTR Tell Us About Lung Disease?
eCysticFibrosis Review
by eCysticFibrosis Review
1y ago
Volume 4, Issue 12. In this issue our guest author is Dr. Patrick Sosnay, Assistant Professor at the Johns Hopkins Cystic Fibrosis Center. Dr. Sosnay will illustrate how the genetics of CF can be used to make a diagnosis or identify a CF carrier, predict how individuals with a given mutation will do clinically and allow clinicians to select currently available and hopefully future therapies that directly address the defect caused by their individual CFTR mutations. The post What Does CFTR Tell Us About Lung Disease? appeared first on DKBmed Radio. Hosted on Acast. See acast.com/privacy for ..read more
Visit website

Follow eCysticFibrosis Review on FeedSpot

Continue with Google
Continue with Apple
OR